NEWS

We are honoured to have been announced as highly commended in the Innovation category of the 2022 Cambridge Independent Science & Technology...

We are delighted that the Milner Therapeutics Institute has been announced as a finalist for the Award for Innovation in the 2021-2022 Cambridge...

We were delighted to welcome George Freeman MP, the Parliamentary under Secretary of State in the Department for Business, Energy and Industrial...

The President of Cyprus, Nicos Anastasiades, presented our Director Tony Kouzarides with the prestigious Excellence in Science Award this week, on...

This week, Deputy Director Kathryn Chapman and Communications Manager Nikki Mann represented the Milner team at the OBN Awards in Oxford, and we are...

We are delighted to share that KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) has joined as an Affiliated Organization of...

We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global...

We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful...

Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein...

Namshik Han's group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40...

We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite...

Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid...

Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a...

We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in...

We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the...

Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed...

Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early...

We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and...

We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been...

Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were...

We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading...

The Jeffrey Cheah Biomedical Centre illuminated blue tonight, to honour the incredible work of our NHS. Milner Institute Director Professor Tony...

We have been busy adapting plans for the coming months, and are pleased to announce that our Milner seminars are moving online. The first talk is...

Thank you to the numerous Milner affiliated companies who have been in contact to offer support  to the University and NHS at this time. Help tackle...

As part of the response to COVID-19 at the University of Cambridge, the Milner Therapeutics Institute will be closed for non-essential business from...

We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings...

We are excited to be celebrating the launch of the AstraZeneca-Cancer Research UK Functional Genomics Centre today. Based in the Milner Therapeutics...

A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute...

A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using...

The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by...

We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a...

We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex,...

Administrator and Finance Coordinator We are looking to appoint a new and key role in our brand new purpose built facilities in the Jeffrey Cheah...

The Milner Therapeutics Symposium 2019 is part of Cambridge Biotech Week (25-28th June), a festival of events focused on accelerating scientific...

This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.

Registration for the Milner Therapeutics Symposium on June 25th 2019 is now open! This Symposium is an opportunity for scientists from academia and...

Our Annual Symposium is an opportunity for scientists from academia and industry to discuss the latest...

  Computational Biology Programme Lead Namshik Han was on the panel at #Impact18 earlier this month, discussing how artificial intelligence is...

SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today...

Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases Milner...

Our new building is starting to take shape now, ready for the opening in October.   The Milner Therapeutics Institute will have research...